Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0L8R9)

Drug Name

ORIC-944 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Embryonic ectoderm development protein (EED)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MAK683	DMFK5IX	Diffuse large B-cell lymphoma	2A81	Phase 1/2	[3]
A-395	DMSTZ14	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Embryonic ectoderm development protein (EED)	TTFNJ4R	EED_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05413421) An Open-Label, Phase 1/1b, Study of ORIC-944 in Patients With Metastatic Prostate Cancer. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of ORIC Pharmaceuticals
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. Nat Chem Biol. 2017 Apr;13(4):389-395.